FrancophonIA/ELRC3.0 huggingface dataset:
English: Infliximab with or without AZA was assessed in a randomised, double-blind, active comparator study (SONIC) of 508 adult patients with moderate to severe Crohn's disease (CDAI ≥ 220 ≤ 450) who were naive to biologics and immunosuppressants and had a median disease duration of 2.3 years.
Slovenian: Uporabo infliksimaba z ali brez AZA so ovrednotili v randomizirani, dvojno slepi študiji s kontrolno učinkovino (SONIC) pri 508 odraslih bolnikih z zmerno do hudo bliko Crohnove bolezni (CDAI ≥ 220 ≤ 450), ki pred tem niso še nikoli prejemali bioloških zdravil ali imunosupresivov in je bila pri njih mediana vrednost trajanja bolezni 2,3 leta.
English: Remicade may be stored at temperatures up to a maximum of 25 °C for a single period of up to 6 months, but not exceeding the original expiry date.
Slovenian: Zdravilo Remicade se lahko shranjuje pri temperaturah do največ 25 °C za enkratno obdobje do 6 mesecev, vendar ne dlje od originalnega datuma izteka roka uporabnosti.
English: For preparation and administration instructions, see section 6.6.
Slovenian: Za navodila glede priprave zdravila in njegove uporabe glejte poglavje 6.6.
English: Of infliximab-treated patients who had an infusion reaction during the induction period, through week 6, 27% experienced an infusion reaction during the maintenance period, week 7 through week 54.
Slovenian: Med bolniki, zdravljenimi z infliksimabom, ki so imeli z infuzijo povezano reakcijo v času uvajalne faze zdravljenja do 6. tedna, je v času vzdrževalnega zdravljenja, to je od 7. do 54. tedna, z infuzijo povezano reakcijo imelo 27 % bolnikov.
English: In rheumatoid arthritis clinical studies, the incidence of serious infections was greater in infliximab plus methotrexate-treated patients 65 years and older (11.3%) than in those under 65 years of age
Slovenian: V kliničnih študijah revmatoidnega artritisa je bila pri bolnikih, ki so se zdravili z infliksimabom in metotreksatom ter so bili stari 65 let ali več, incidenca resnih okužb večja (11,3 %) kot pri tistih, ki so bili mlajši od 65 let (4,6 %).
English: • Your doctor will test you to see if you have TB.
Slovenian: • Zdravnik bo opravil tuberkulinski test, da ugotovi ali imate tuberkulozo.
English: • Tell your doctor if you have any abnormal skin openings (fistulae) before you are given
Slovenian: • Obvestite zdravnika, če imate na koži nenormalne odprtine (fistule), preden začnete prejemati zdravilo Remicade.
English: Dilute the total volume of the reconstituted Remicade solution dose to 250 ml with sodium chloride 9 mg/ml (0.9%) solution for infusion.
Slovenian: Celoten volumen (odmerek) rekonstituirane raztopine zdravila Remicade razredčite do 250 ml z 9 mg/ml (0,9 %) raztopino natrijevega klorida za infundiranje.
English: • Eye problems including blurred or reduced vision, puffy eyes or sties
Slovenian: • težave z očmi, vključno z zamegljenim vidom ali slabovidnostjo, otečene oči ali ječmen na očesu
English: Infliximab Maintenance (5 mg/kg) (n = 96)
Slovenian: Vzdrževalno zdravljenje z infliksimabom (5 mg/kg) (n = 96)
English: Infliximab Maintenance 5 mg/kg (n = 113) (p value)
Slovenian: Vzdrževalno zdravljenje z infliksimabom 5 mg/kg (n = 113) (p vrednost)
English: Patients with no deterioration/patients evaluated
Slovenian:  SD mediana (interkvartilni razmik) bolniki brez poslabšanja/ pregledani bolniki (%)
English: Patients who developed antibodies to infliximab were more likely (approximately 2-3 fold) to develop infusion-related reactions.
Slovenian: Pri bolnikih, pri katerih so se pojavila protitelesa proti infliksimabu, je verjetnost za pojav z infuzijo povezanih reakcij večja (približno 2 do 3-krat).
English: In the post-marketing setting, cases of leukaemia have been reported in patients treated with a TNF-antagonist.
Slovenian: Pri spremljanju zdravila v obdobju trženja so poročali o primerih levkemije pri bolnikih zdravljenjih z antagonisti TNF.
English: Significantly fewer colectomies occurred within 3 months of study infusion in patients who received a single dose of 5 mg/kg infliximab compared to patients who received placebo (29.2% vs. 66.7% respectively, p = 0.017).
Slovenian: V 3 mesecih infundiranja zdravila v okviru te študije je bilo pri bolnikih, ki so prejeli en sam odmerek infliksimaba 5 mg/kg, opravljenih bistveno manj kolektomij kot pri tistih, ki so prejemali placebo (29,2 % v primerjavi s 66,7 %, p = 0,017).
English: In the second clinical study (ASSERT), 279 patients were randomised to receive either placebo (Group 1, n = 78) or 5 mg/kg infliximab (Group 2, n = 201) at 0, 2 and 6 weeks and every 6 weeks to week 24.
Slovenian: V drugem preskušanju (ASSERT) so 279 bolnikov naključno razporedili bodisi v skupino, ki bo prejemala placebo (1. skupina, n = 78), ali pa v skupino, ki bo prejemala infliksimab v odmerku 5 mg/kg (2. skupina, n = 201) v 0., 2. in 6. tednu in kasneje na vsakih 6 tednov, do 24. tedna.
English: • Collection of blood outside the blood vessels (haematoma) or bruising
Slovenian: • kopičenje krvi izven krvnih žil (hematom) ali nastajanje podplutb
English: Antibodies to infliximab may develop and have been associated with an increased frequency of infusion reactions.
Slovenian: Pojavijo se lahko protitelesa proti infliksimabu, ki so bila povezana s povečano pogostnostjo z infuzijo povezanih reakcij.
English: Maintenance treatment in moderately to severely active Crohn's disease in adults The efficacy of repeated infusions with infliximab was studied in a 1-year clinical study (ACCENT I).
Slovenian: Vzdrževalno zdravljenje pri zmerno do močno aktivni Crohnovi bolezni pri odraslih bolnikih Učinkovitost večkratnih infuzij infliksimaba so ocenjevali v enoletni klinični študiji (ACCENT I).
English: Patients who discontinue immunosuppressants prior to or during Remicade treatment are at greater risk of developing these antibodies.
Slovenian: Pri bolnikih, ki prekinejo zdravljenje z zdravili za zaviranje imunske odzivnosti bodisi pred uvedbo zdravljenja z zdravilom Remicade ali med njim, je nevarnost za pojav teh protiteles večja.
English: Infliximab
Slovenian: Infliksimab
English: There have been post-marketing reports of worsening heart failure, with and without identifiable precipitating factors, in patients taking Remicade.
Slovenian: Iz obdobja trženja obstajajo poročila o poslabševanju srčnega popuščanja pri bolnikih, ki so jemali zdravilo Remicade, z ali brez ugotovljivih dejavnikov, ki bi lahko poslabšali stanje.
English: A population-based retrospective cohort study found an increased incidence of cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-naïve patients or the general population, including those over 60 years of age (see section 4.4).
Slovenian: V populacijski retrospektivni kohortni študiji so ugotovili povečano pojavnost raka materničnega vratu pri ženskah z revmatoidnim artritisom in zdravljenih z infliksimabom, v primerjavi z bolnicami, ki še niso prejemale bioloških zdravil, ali s splošno populacijo, vključno s starejšimi od 60 let (glejte poglavje 4.4).
English: Some cases have had fatal outcome.
Slovenian: V nekaterih primerih je prišlo celo do smrtnega izida.
English: Remicade should be administered intravenously.
Slovenian: Zdravilo Remicade je treba dajati intravensko.
English: If serious reactions occur, symptomatic treatment must be given and further Remicade infusions must not be administered (see section 4.8).
Slovenian: Če se pojavijo resne reakcije, morate uvesti simptomatično zdravljenje in bolniku ne smete več dajati infuzij tega zdravila (glejte poglavje 4.8).
English: Caution should be exercised when considering the use of Remicade in patients with chronic infection or a history of recurrent infections, including concomitant immunosuppressive therapy.
Slovenian: Pri odločanju o uporabi zdravila Remicade pri bolnikih s kroničnimi okužbami ali ponavljajočimi se okužbami v pretekli anamnezi, pa tudi pri tistih, s sočasno imunosupresivno terapijo, je potrebna previdnost.
English: If these medicines do not work well enough, you will be given Remicade to:
Slovenian: Če ta zdravila ne delujejo dovolj dobro, boste prejeli zdravilo Remicade za:
English: It is recommended that live vaccines not be given concurrently with Remicade.
Slovenian: Priporočamo, da živih cepiv ne dajete sočasno z zdravilom Remicade.
English: The most serious ADRs associated with the use of TNF blockers that have been reported for Remicade include HBV reactivation, CHF (congestive heart failure), serious infections (including sepsis, opportunistic infections and TB), serum sickness (delayed hypersensitivity reactions), haematologic reactions, systemic lupus erythematosus/lupus-like syndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia, Merkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid-like reaction, intestinal or perianal abscess (in Crohn's disease), and serious infusion reactions (see section 4.4).
Slovenian: Med najresnejše, z uporabo zaviralcev TNF povezane neželene učinke zdravila, o katerih so poročali pri uporabi zdravila Remicade, sodijo reaktivacija HBV, kongestivno srčno popuščanje (CHF - congestive heart failure), resne okužbe (vključno s sepso, oportunističnimi okužbami in TB), serumska bolezen (zapoznele preobčutljivostne reakcije), hematološke reakcije, sistemski eritematozni lupus/lupusu podoben sindrom, demielinizirajoče bolezni, dogodki povezani z jetri ali žolčnikom, limfom, hepatosplenični limfom celic T (HSTCL), levkemija, karcinom Merklovih celic, melanom, pojav malignomov pri otrocih, sarkoidoza/sarkoidozi podobne reakcije, črevesni ali perianalni absces (pri Crohnovi bolezni) ter resne z infuzijo povezane reakcije (glejte poglavje 4.4).
English: Table 3 Effects on ACR20, Structural Joint Damage and Physical Function at week 54, ATTRACT infliximab
Slovenian: Preglednica 3 Učinki na ACR 20, strukturno okvaro sklepov in funkcijo sklepov v 54. tednu, študija ATTRACT
English: At week 24, the number of ASAS 20 responders was 15/78 (19%) in the placebo group, and 123/201 (61%) in the 5 mg/kg infliximab group (p < 0.001).
Slovenian: V 24. tednu je število bolnikov z odzivom ASAS 20 znašalo 15 od 78 (19 %) v skupini za placebo in 123 od 201 (61 %) v skupini, ki je prejemala infliksimab v odmerku 5 mg/kg (p < 0,001).
English: The most common adverse event was worsening of ulcerative colitis, the incidence of which was higher in patients on the q12 week vs. the q8 week dosing regimen.
Slovenian: Najpogostejši neželeni učinek je bil poslabšanje ulceroznega kolitisa, pogostnost katerega je bila večja pri bolnikih, ki so zdravilo prejemali na 12 tednov, kot pri bolnikih, ki so zdravilo prejemali na 8 tednov.
English: • Low platelet count, too many white blood cells
Slovenian: • nizko število trombocitov, preveliko število belih krvnih celic
English: Patients on infliximab may receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6).
Slovenian: Bolniki, ki prejemajo infliksimab, lahko sočasno prejmejo cepiva, razen živih cepiv (glejte poglavji 4.5 in 4.6).
English: Remicade is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or PUVA (see section 5.1).
Slovenian: Zdravilo Remicade je indicirano za zdravljenje zmerne do hude psoriaze s plaki pri odraslih bolnikih, ki se niso odzvali na druge sistemske terapije, na primer ciklosporine, metotreksat ali PUVA (glejte poglavje 5.1), ali pa imajo kontraindikacijo zanje ali jih ne prenašajo.
English: In patients with pre-existing or recent onset of demyelinating disorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation of Remicade therapy.
Slovenian: Pri bolnikih z obstoječo ali nedavno nastalo demielinizirajočo boleznijo morate pred uvedbo terapije z zdravilom Remicade skrbno pretehtati razmerje med tveganji in koristmi anti-TNF zdravljenja za bolnika.
English: Limited experience from re-treatment following disease flare by a re-induction regimen suggests a higher incidence of infusion reactions, including serious ones, when compared to 8-weekly maintenance treatment (see section 4.8).
Slovenian: izkušnje s ponovno uporabo uvodne sheme, so pokazale večjo incidenco z infuzijo povezanih reakcij, vključno z resnimi z infuzijo povezanimi reakcijami, v primerjavi z 8-tedenskim vzdrževalnim zdravljenjem (glejte poglavje 4.8).
English: For results see Table 6.
Slovenian: Rezultati študije so podani v preglednici 6.
English: In rheumatoid arthritis, psoriatic arthritis and Crohn's disease patients, there are indications that concomitant use of methotrexate and other immunomodulators reduces the formation of antibodies against infliximab and increases the plasma concentrations of infliximab.
Slovenian: Obstajajo znaki, da sočasna uporaba metotreksata in drugih imunomodulatorjev pri bolnikih z revmatoidnim artritisom, psoriatičnim artritisom in Crohnovo boleznijo zmanjša tvorbo protiteles proti infliksimabu in poveča koncentracijo infliksimaba v plazmi.
English: Use of concomitant immunosuppressant agents appeared to reduce the frequency of infusion-related reactions.
Slovenian: Zdi se, da sočasna uporaba zdravil za zaviranje imunske odzivnosti zmanjša pogostnost z infuzijo povezanih reakcij.
English: It is recommended that therapeutic infectious agents not be given concurrently with Remicade (see section 4.4).
Slovenian: Priporočamo, da povzročiteljev okužb v terapevtske namene ne dajete sočasno z zdravilom Remicade (glejte poglavje 4.4).
English: PGA of cleared (0) or minimal (1) PGA of cleared (0), minimal (1), or mild (2) All nails cleared
Slovenian: PGA brez plakov (0) ali minimalni (1) PGA brez plakov (0), minimalni (1), ali blagi (2) Vsi nohti brez psoriatičnih sprememb 10. teden
English: For intravenous use after reconstitution and dilution.
Slovenian: intravenska uporaba po rekonstituciji in redčenju
English: For patients receiving corticosteroids at baseline, the proportion of patients in remission and not receiving corticosteroids at week 54 was 38.5% (5/13) for the q8 week and 0% (0/13) for the q12 week maintenance treatment group.
Slovenian: Med bolniki, ki so na začetku dobivali kortikosteroide, je bil delež tistih v remisiji in brez uporabe kortikosteroidov v 54. tednu 38,5 % (5/13) v skupini, ki je dobivala vzdrževalno zdravljenje na 8 tednov, in 0 % (0/13) v skupini, ki je dobivala vzdrževalno zdravljenje na 12 tednov.
English: There were 53 subjects who continued on 5 mg/kg every 6 weeks.
Slovenian: Skupaj 53 preiskovancev je nadaljevalo z jemanjem odmerka 5 mg/kg na vsakih 6 tednov.
English: Additional side effects in children and adolescents Children who took Remicade for Crohn's disease showed some differences in side effects compared with adults who took Remicade for Crohn's disease.
Slovenian: Dodatni neželeni učinki pri otrocih in mladostnikih Neželeni učinki pri otrocih in odraslih, ki so prejemali zdravilo Remicade za zdravljenje Crohnove bolezni, so se nekoliko razlikovali.
English: Elevated concentrations of TNF have been found in the joints of rheumatoid arthritis patients and correlate with elevated disease activity.
Slovenian: V sklepih bolnikov z revmatoidnim artritisom so ugotavljali povečano koncentracijo TNF in ta je bila v korelaciji s povečano aktivnostjo bolezni.
English: • Psoriasis, skin problems such as eczema and hair loss
Slovenian: • luskavica, kožne težave, kot na primer ekcem, in izpadanje las
English: Do not store any unused portion of the infusion solution for reuse.
Slovenian: Neporabljenega ostanka raztopine za infundiranje ne smete shraniti za poznejšo uporabo.
English: Repeated administration of infliximab (5 mg/kg at 0, 2 and 6 weeks in fistulising Crohn's disease, 3 or 10 mg/kg every 4 or 8 weeks in rheumatoid arthritis) resulted in a slight accumulation of infliximab in serum after the second dose.
Slovenian: Po večkratni uporabi infliksimaba (5 mg/kg na začetku, v 2. in 6. tednu pri Crohnovi bolezni s fistulami oz. 3 ali 10 mg/kg na vsake 4 ali 8 tednov pri revmatoidnem artritisu) so ugotavljali blago kopičenje zdravila v serumu po drugem odmerku.
English: Remicade is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and
Slovenian: Zdravilo Remicade je indicirano za zdravljenje zmerno do močno aktivnega ulceroznega kolitisa pri odraslih bolnikih, ki so se nezadostno odzvali na običajno zdravljenje, na primer na kortikosteroide in
English: Signs and symptoms included myalgia and/or arthralgia with fever and/or rash, with some patients experiencing pruritus, facial, hand or lip oedema, dysphagia, urticaria, sore throat and headache.
Slovenian: Med znaki in simptomi so bili mialgija in/ali artralgija z zvišano telesno temperaturo in/ali izpuščajem, pri nekaterih bolnikih pa so se pojavili srbenje, edem obraza, dlani ali ustnic, disfagija, urtikarija, vnetje žrela in glavobol.
English: Signs include yellowing of the skin and eyes, dark-brown coloured urine, pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever.
Slovenian: Znaki vključujejo porumenelost kože in oči, temno rjavo obarvan urin, bolečino ali oteklino na zgornji desni strani želodčnega predela, bolečino v sklepih, kožne izpuščaje ali zvišano telesno temperaturo.
English: Percentage of subjects in clinical remission and sustained remission Clinical remission at week 8
Slovenian: Odstotek preiskovancev v klinični remisiji in trajnejši remisiji Klinična remisija v 8. tednu
English: The safety and efficacy of Remicade have not been studied in children with ulcerative colitis below the age of 6 years.
Slovenian: Varnost in učinkovitost zdravila Remicade pri otrocih z ulceroznim kolitisom, mlajših od 6 let, niso preučevali.
English: Concurrent administration of TNF-alpha inhibitor and abatacept In clinical studies concurrent administration of TNF-antagonists and abatacept has been associated with an increased risk of infections including serious infections compared to TNF-antagonists alone, without increased clinical benefit.
Slovenian: Sočasna uporaba zaviralcev TNF-alfa in abatacepta V kliničnih študijah je bila sočasna uporaba antagonistov TNF in abatacepta povezana z večjim tveganjem za okužbe (vključno z resnimi okužbami) kot pa uporaba samih antagonistov TNF, čeprav ni prišlo do povečanja kliničnega učinka.
English: All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after Remicade treatment.
Slovenian: Vsem bolnikom morate naročiti, naj pridejo k zdravniku, če se v času zdravljenja z zdravilom Remicade ali po njem pojavijo znaki ali simptomi, ki kažejo na tuberkulozo (npr. trdovraten kašelj, hujšanje ali nekoliko zvišana telesna temperatura).
English: In group 2, starting with the week 36 infusion, patients who had a BASDAI ≥ 3 at 2 consecutive visits, received 7.5 mg/kg infliximab every 6 weeks thereafter through week 96.
Slovenian: 1. skupina je prejemala 5 mg/kg infliksimaba, v 2. skupini pa so od infuzije v 36. tednu vsi bolniki, ki so imeli BASDAI ≥ 3 pri 2 zaporednih obiskih, prejemali po 7,5 mg/kg infliksimaba na vsakih 6. tednov, do 96. tedna.
English: A greater proportion of patients in the combined infliximab treatment group were able to discontinue corticosteroids while remaining in clinical remission compared to the placebo treatment group at both week 30 (22.3% vs. 7.2%, p < 0.001, pooled ACT 1 & ACT 2 data) and week 54 (21.0% vs. 8.9%, p = 0.022, ACT1 data).
Slovenian: V (združeni) skupini, ki se je zdravila z infliksimabom, so pri večjem odstotku bolnikov lahko ukinili kortikosteroide ob ohranjeni klinični remisiji kot pri skupini, ki je prejemala placebo, kar velja tako za 30. teden (22,3 % v primerjavi s 7,2 %, p < 0,001, združeni podatki iz preskušanj ACT1 in ACT2) kot za 54. teden (21,0 % v primerjavi z 8,9 %, p = 0,022, podatki iz preskušanja ACT1).
English: Remicade is indicated for treatment of severe, active Crohn's disease, in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.
Slovenian: Zdravilo Remicade je indicirano za zdravljenje hude, aktivne Crohnove bolezni pri otrocih in mladostnikih, starih od 6 do 17 let, ki se niso odzvali na običajno terapijo, vključno s kortikosteroidi, imunomodulatorji in primarno prehransko terapijo, ter pri tistih, ki ne prenašajo teh običajnih načinov zdravljenja oziroma imajo kontraindikacije zanje.
English: Patients should be advised of and avoid exposure to potential risk factors for infection as appropriate.
Slovenian: Bolnike poučite o potencialnih dejavnikih tveganja za okužbe in jim svetujte, naj se izogibajo izpostavljanju le-tem, odvisno od primera.
English: ≥ 50% improvement
Slovenian: ≥ 50 % izboljšanje
English: Infliximab Maintenance 10 mg/kg (n = 112) (p value)
Slovenian: Vzdrževalno zdravljenje z infliksimabom 10 mg/kg (n = 112) (p vrednost)
English: Date of Remicade therapy initiation:
Slovenian: Datum začetka zdravljenja z zdravilom Remicade:
English: In Phase III clinical studies, 18% of infliximab-treated patients compared with 5% of placebo-treated patients experienced an infusion-related reaction.
Slovenian: V kliničnih študijah faze III se je pri 18 % bolnikov zdravljenih z infliksimabom med infundiranjem pojavila z infuzijo povezana reakcija, v primerjavi s 5 % bolnikov, ki so prejemali placebo.
English: Remicade is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.
Slovenian: Zdravilo Remicade je indicirano za zdravljenje močno aktivnega ulceroznega kolitisa pri otrocih in mladostnikih, starih od 6 do 17 let, ki so se nezadostno odzvali na običajno zdravljenje, na primer na kortikosteroide in 6-MP ali AZA, ter pri tistih, ki ne prenašajo takšnega zdravljenja ali imajo medicinske kontraindikacije zanj.
English: Infliximab prevented disease in transgenic mice that develop polyarthritis as a result of constitutive expression of human TNF and when administered after disease onset, it allowed eroded joints to heal.
Slovenian: Infliksimab je preprečil razvoj poliartritisa pri transgenskih miših, pri katerih ta bolezen nastopi kot posledica konstitucijske ekspresije humanega TNF.
English: Week 54
Slovenian: 54. teden
English: In both studies, patients were randomised to receive either placebo, 5 mg/kg Remicade, or 10 mg/kg Remicade at weeks 0, 2, 6, 14 and 22, and in ACT 1 at weeks 30, 38 and 46.
Slovenian: V obeh študijah so bili bolniki randomizirani bodisi v skupino za placebo, skupino, ki je prejemala 5 mg/kg zdravila Remicade, ali pa v skupino, ki je prejemala 10 mg/kg zdravila Remicade v 0., 2., 6., 14. in 22. tednu in v ACT 1 v 30., 38. in 46. tednu.
English: If you were using Remicade during pregnancy, tell your baby's doctor and other healthcare professionals caring for your baby about your Remicade use before the baby receives any vaccines.
Slovenian: Če ste prejemali zdravilo Remicade med nosečnostjo, je pomembno, da o tem obvestite otrokovega zdravnika in druge zdravstvene delavce, ki skrbijo za vašega dojenčka, preden vaš dojenček prejme katero koli cepivo.
English: Remicade and Kineret should not be used together.
Slovenian: Zdravili Remicade in Kineret se ne smeta uporabljati skupaj.